High prevalence of advanced fibrosis in association with the metabolic syndrome in a Belgian prospective cohort of NAFLD patients with elevated ALT. results of the Belgian NAFLD registry

Acta Gastro-Enterologica Belgica

Volumn 74, Issue 1, 2011, Pages 9-16

  Francque, S ^a   de Maeght, S ^b   Adler, M ^c   Deltenre, P ^b   de Galocsy, C ^d   Orlent, H ^e   van Steenbergen, W ^f   Bastens, B ^g   Wain, E ^h   Langlet, P ^c   Lasser, L ^c   Verlinden, W ^a   van Marck, E ^a   Henrion, J ^b  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b Department of Gastro enterology ^*  (Belgium)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^d HIS Bracops Department of Gastro enterology   (Belgium)

^e General Hospital St Jan   (Belgium)

^f UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^g Hopital St Joseph   (Belgium)

^h CH Verviers Department of gastro enterology   (Belgium)

Author keywords

Diabetes; Fibrosis; Ggt; Overweight; Steatosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; TETRAHYDROLIPSTATIN; URSODEOXYCHOLIC ACID;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; BELGIUM; BODY MASS; DIABETES MELLITUS; DISEASE SEVERITY; DYSLIPIDEMIA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; INSULIN TREATMENT; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; PROSPECTIVE STUDY; SEX RATIO;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; BELGIUM; COHORT STUDIES; FATTY LIVER; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; REGISTRIES; YOUNG ADULT;

EID: 79956287499     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. BUGIANESI E., BELLENTANI S., BEDOGNI G., TIRIBELLI C. Clinical update on non-alcoholic fatty liver disease and steatohepatitis. Ann. Hepatol., 2008, 7: 157-160.
2. BUGIANESI E., LEONE N., VANNI E., MARCHESINI G., BRUNELLO F., CARUCCI P., MUSSO A., DE PAOLIS P., CAPUSSOTTI L., SALIZZONI M., RIZZETTO M. Expanding the natural history of non - alcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology, 2002, 123: 134-140.
3. ANGULO P. Nonalcoholic fatty liver disease. N. Engl. J. Med., 2002, 346: 1221-1231.
4. FRANCQUE S. Non-alcoholic fatty liver disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). Oxford Textbook of Public Health. 5 ed. Oxford University Press, 2009, 1249-1263.
5. BELLENTANI S., SACCOCCIO G., MASUTTI F., CROCE L.S., BRANDI G., SASSO F., CRISTANINI G., TIRIBELLI C. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med., 2000, 132 112-117.
6. NEUSCHWANDER-TETRI B.A., CALDWELL S.H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology, 2003, 37: 1202-1219.
7. RUHL C.E., EVERHART J.E. Epidemiology of nonalcoholic fatty liver. Clin. Liver Dis., 2004, 8 501-519, vii.
8. BUGIANESI E., VANNI E., MARCHESINI G. NASH. The risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes. Curr. Diab. Rep., 2007, 7: 175-180.
9. HILDEN M., CHRISTOFFERSEN P., JUHL E., DALGAARD J.B. Liver histology in a 'normal' population - examinations of 503 consecutive fatal traffic casualties. Scand. J. Gastroenterol., 1977, 12: 593-597.
10. ANGULO P., KEACH J.C., BATTS K.P., LINDOR K.D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology, 1999, 30: 1356-1362.
11. MARCHESINI G., BUGIANESI E., FORLANI G., CERRELLI F., LENZI M., MANINI R., NATALE S., VANNI E., VILLANOVA N., MELCHIONDA N., RIZZETTO M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology, 2003, 37: 917-923.
12. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA, 2001, 285: 2486-2497.
13. JUNG R.T. Obesity as a disease. Br. Med. Bull., 1997, 53: 307-321.
14. FARRELL G.C., GEORGE J., DE LA M. HALL P., MC CULLOUGH A.J. An introduction to NASH and related fatty liver disorders. In: FARRELL G.C., GEORGE J., DE LA M. HALL P., MC CULLOUGH A.J. (eds). Fatty Liver Disease: NASH and Related Disorders. 1 ed. Massachusetts: Blackwell Publishing, 2005, 1-12.
15. ALBERTI K.G., ZIMMET P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med., 1998, 15: 539-553.
16. CHOBANIAN A.V., BAKRIS G.L., BLACK H.R., CUSHMAN W.C., GREEN L.A., IZZO J.L. JR., JONES D.W., MATERSON B.J., OPARIL S., WRIGHT J.T. JR., ROCCELLA E.J. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure the JNC 7 report. JAMA, 2003, 289: 2560-2572.
17. PIGNONE M. Primary prevention: dyslipidaemia. Clin. Evid., 2005, 142-150.
18. ALBERTI K.G., ZIMMET P., SHAW J. The metabolic syndrome - a new worldwide definition. Lancet, 2005, 366: 1059-1062.
19. BRUNT E.M., JANNEY C.G., DI BISCEGLIE A.M., NEUSCHWANDERTETRI B.A., BACON B.R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol., 1999, 94 2467-2474.
20. KLEINER D.E., BRUNT E.M., VAN N.M., BEHLING C., CONTOS M.J., CUMMINGS O.W., FERRELL L.D., LIU Y.C., TORBENSON M.S., UNALP-ARIDA A., YEH M., MC CULLOUGH A.J., SANYAL A.J. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 2005, 41 1313-1321.
21. MOREAU M., VALENTE F., MAK R., PELFRENE E., DE SMET P., DE BACKER G., KORNITZER M. Obesity, body fat distribution and incidence of sick leave in the Belgian workforce: the Belstress study. Int. J. Obes. Relat. Metab. Disord., 2004, 28: 574-582.
22. EGUCHI Y., EGUCHI T., MIZUTA T., IDE Y., YASUTAKE T., IWAKIRI R., HISATOMI A., OZAKI I., YAMAMOTO K., KITAJIMA Y., KAWAGUCHI Y., KUROKI S., ONO N. Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease. J. Gastroenterol., 2006, 41: 462-469.
23. HU G., QIAO Q., TUOMILEHTO J., BALKAU B., BORCH-JOHNSEN K., PYORALA K. Prevalence of the metabolic syndrome and its relation to allcause and cardiovascular mortality in nondiabetic European men and women. Arch. Intern. Med., 2004, 164: 1066-1076.
24. MICCOLI R., BIANCHI C., ODOGUARDI L., PENNO G., CARICATO F., GIOVANNITTI M.G., PUCCI L., DEL P.S. Prevalence of the metabolic syndrome among Italian adults according to ATP III definition. Nutr. Metab. Cardiovasc. Dis., 2005, 15: 250-254.
25. ADAMS L.A., LYMP J.F., ST. SAUVER J., SANDERSON S.O., LINDOR K.D., FELDSTEIN A., ANGULO P. The natural history of non - alcoholic fatty liver disease: a population-based cohort study. Gastroenterology, 2005, 129: 113-121.
26. DE MARCO R., LOCATELLI F, ZOPPINI G, VERLATO G, BONORA E, MUGGEO M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care, 1999, 22: 756-761.
27. FASSIO E., ALVAREZ E., DOMINGUEZ N., LANDEIRA G., LONGO C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology, 2004, 40: 820-826.
28. DAM-LARSEN S., FRANZMANN M., ANDERSEN I.B., CHRISTOFFERSEN P., JENSEN L.B., SORENSEN T.I., BECKER U., BENDTSEN F. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut, 2004, 53 750-755.
29. EKSTEDT M., FRANZEN L.E., MATHIESEN U.L., THORELIUS L., HOLMQVIST M., BODEMAR G., KECHAGIAS S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology, 2006, 44: 865-873.
30. ABRAMS G.A., KUNDE S.S., LAZENBY A.J., CLEMENTS R.H. Portal fibrosis and hepatic steatosis in morbidly obese subjects: A spectrum of nonalcoholic fatty liver disease. Hepatology, 2004, 40: 475-483.
31. BUGIANESI E., MC CULLOUGH A.J., MARCHESINI G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology, 2005, 42: 987-1000.
32. MARRA F., BERTOLANI C. Adipokines in liver diseases. Hepatology, 2009, 50: 957-969.
33. VANNI E., BUGIANESI E., KOTRONEN A., DE MINICIS S., YKIJARVINEN H., SVEGLIATI-BARONI G. From the metabolic syndrome to NAFLD or vice versa? Dig. Liver Dis., 2010, 42: 320-330.
34. RATZIU V., GIRAL P., CHARLOTTE F., BRUCKERT E., THIBAULT V., THEODOROU I., KHALIL L., TURPIN G., OPOLON P., POYNARD T. Liver fibrosis in overweight patients. Gastroenterology, 2000, 118: 1117- 1123.
35. MOFRAD P., CONTOS M.J., HAQUE M., SARGEANT C., FISHER R.A., LUKETIC VA., STERLING R.K., SHIFFMAN M.L., STRAVITZ R.T., SANYAL A.J. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology, 2003, 37: 1286-1292.
36. PRATI D., TAIOLI E., ZANELLA A., DELLA TE., BUTELLI S., DEL V.E., VIANELLO L., ZANUSO F., MOZZI F., MILANI S., CONTE D., COLOMBO M., SIRCHIA G. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann. Intern. Med., 2002, 137: 1-10.
37. KUNDE S.S., LAZENBY A.J., CLEMENTS R.H., ABRAMS G.A. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology, 2005, 42: 650-656.
38. IMBERT-BISMUT F., RATZIU V., PIERONI L., CHARLOTTE F., BENHAMOU Y., POYNARD T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet, 2001, 357: 1069-1075.
39. OMAGARI K., KADOKAWA Y., MASUDA J., EGAWA I., SAWA T., HAZAMA H., OHBA K., ISOMOTO H., MIZUTA Y., HAYASHIDA K., MURASE K., KADOTA T., MURATA I., KOHNO S. Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J. Gastroenterol. Hepatol., 2002, 17: 1098-1105.
40. VERRIJKEN A., FRANCQUE S., MERTENS I., TALLOEN M., PEIFFER F., VAN GAAL L. Visceral adipose tissue and inflammation correlate with elevated liver tests in a cohort of overweight and obese patients. Int. J. Obes. (Lond.), 2010, 34: 899-907.
41. RYAN C.K., JOHNSON L.A., GERMIN B.I., MARCOS A. One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transpl., 2002, 8: 1114-1122.
42. MOTTIN C.C., MORETTO M., PADOIN A.V., SWAROWSKY A.M., TONETO M.G., GLOCK L., REPETTO G. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes. Surg., 2004, 14: 635-637.